[Exertion-electrocardiographic and hemodynamic studies with oral verapamil in chronic ischemic heart disease].
The effect of the Ca++ -antagonist Verapamil on the ECG, the haemodynamic parameters and the systolic time intervals was investigated in the long-term experiment on 12 patients with ascertained chronic ischaemic heart disease at reat and during exercise. The dosage was 3 x 80 mg/die during 4 weeks. The tolerance was not increased. The load-induced decrease of the ST-T-distance in the ECG was improved under load and in the recreation phase. The function of the myocardium, measured on the quotient LVET/ICT, improved under load with simultaneous decrease of the double product and the TTI, the pulmonary pressure, however, remained uninfluenced. Side-effects were not observed.
D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D003327:Coronary Disease / Q000175:diagnosis* / Q000188:drug therapy; D004341:Drug Evaluation; D004562:Electrocardiography; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D005996:Nitroglycerin / Q000627:therapeutic use; D005082:Physical Exertion; D011651:Pulmonary Artery; D014700:Verapamil / Q000627:therapeutic use*
D014700:Verapamil; D005996:Nitroglycerin
Belastungselektrokardiographische und hämodynamische Untersuchungen mit Oral-Verapamil bei chronisch ischämischer Herzkrankheit.